The noble lord will be aware of the hon. Member for Wallasey\u2019s (Ms Eagle) Westminster Hall debate on 18 November about posthumous recognition for Corporal McLaughlin. Following the debate, the Minister of State for Defence, Personnel, Welfare and Veterans (Anna Soubry) and I have agreed that while a formal investigation is not an option, I will re-examine the facts surrounding recognition in this case. However, to be clear, no citation for an award was received for consideration by the Ministry of Defence and therefore it would be incorrect to say that Cpl McLaughlin had a recommendation withdrawn. The issue is that no citation was actually submitted for consideration by the Operational Awards Committee; a fact that is acknowledged by all parties.<\/p>
<\/p>
<\/p>
<\/p>
<\/p>
<\/p>
<\/p>
<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3428", "label" : {"_value" : "Biography information for Lord Astor of Hever"} } , "answeringMemberPrinted" : {"_value" : "Lord Astor of Hever"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/156456/answer/attachment/1", "fileName" : {"_value" : "Debate Corporal Stewart Mclaughlin 18 November 2014.doc"} , "title" : " DebateHansard Extract 18 November 2014"} , "dateOfAnswer" : {"_value" : "2014-12-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2014-12-01T16:19:25.677Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "11"} , "answeringDeptShortName" : {"_value" : "Defence"} , "answeringDeptSortName" : {"_value" : "Defence"} , "date" : {"_value" : "2014-11-18", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Falkland Islands"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government whether they will revisit the circumstances in which the late Corporal McLaughlin was recommended for a gallantry award during the Falklands conflict which was subsequently withdrawn; and if not, why not.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2568", "label" : {"_value" : "Biography information for Lord Ashcroft"} } , "tablingMemberPrinted" : [{"_value" : "Lord Ashcroft"} ], "uin" : "HL2898"} , {"_about" : "http://data.parliament.uk/resources/156457", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/156457/answer", "answerText" : {"_value" : "
Mefloquine (brand name Lariam) is one of several drugs licensed for the prevention (c<\/strong>hemoprophylaxis) or treatment of malaria. As with any medicine, mefloquine may cause side effects in some people and the potential risks should be balanced against the expected benefits of therapy. Information on possible side effects is available to the medical profession via the Summary of Product Characteristics (SmPC), and to patients via the Patient Information Leaflet.<\/p> <\/p> <\/p> <\/p> In 2013, the Medicines and Healthcare products Regulatory Agency (MHRA) strengthened the warnings in the mefloquine SmPC, particularly regarding the well-established risk of neuropsychiatric side effects. The licence holder (Roche) also issued a letter to healthcare professionals at the end of October 2013 to increase awareness of these possible risks, alongside a prescriber checklist and patient alert card to aid compliance with the warnings. In November 2013, the MHRA issued a further communication to healthcare professionals on the risks of mefloquine via its Drug Safety Update bulletin:<\/p> <\/p> <\/p> <\/p> www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON336723<\/p> <\/p> <\/p> <\/p> As with all medicines, the MHRA will keep the safety of mefloquine under continual review.<\/p> <\/p> <\/p> <\/p> The Advisory Committee for Malaria Prevention (ACMP) carefully considered all available data following the Food and Drug Administration\u2019s safety communication and subsequent modification of the SmPC by Roche in September 2013. SmPC recommendations for monitoring of liver function and eye assessment in long term use have also been added to the guidelines. The ACMP continues to believe that mefloquine is a valuable option for prophylaxis against malaria when appropriate risk assessments are undertaken.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-12-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-02T12:38:24.45Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mefloquine"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what assessment the Medicines and Healthcare Products Regulatory Agency and the Advisory Committee for Malaria Prevention have made of the United States Food and Drug Administration's Safety Communication of 29 July 2013 warning of the risk of psychiatric and nerve side effects from taking Lariam (mefloquine) as a malaria prophylactic.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/215", "label" : {"_value" : "Biography information for Baroness Corston"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Corston"}
], "uin" : "HL2899"}
, {"_about" : "http://data.parliament.uk/resources/156458", "AnsweringBody" : [{"_value" : "Ministry of Defence"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/156458/answer", "answerText" : {"_value" : " 58 UK Armed Forces personnel who have been deployed on Operation GRITROCK before 31 October 2014 have been prescribed Mefloquine (commercially known as Lariam) as a malaria prophylaxis. All of these 58 were Regulars.<\/p> <\/p> The exact choice of antimalarial drug used by the military depends on a number of factors, including the region the individual is deploying to, their health and any past history of side effects. Malarone is the first choice drug for those Service personnel deploying on Operation GRITROCK. For those individuals unable to tolerate Malarone the second choice is Mefloquine. Doxycycline will be offered to those individuals who cannot tolerate Malorone or Mefloquine.<\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3428", "label" : {"_value" : "Biography information for Lord Astor of Hever"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Astor of Hever"}
, "dateOfAnswer" : {"_value" : "2014-12-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-01T16:13:10.08Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "11"}
, "answeringDeptShortName" : {"_value" : "Defence"}
, "answeringDeptSortName" : {"_value" : "Defence"}
, "date" : {"_value" : "2014-11-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Armed Forces: Mefloquine"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government how many serving (1) members of the armed forces, and (2) reservists, deployed to Sierra Leone in the ebola epidemic have been given Lariam (mefloquine) as a malaria prophylaxis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/215", "label" : {"_value" : "Biography information for Baroness Corston"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Corston"}
], "uin" : "HL2900"}
, {"_about" : "http://data.parliament.uk/resources/156459", "AnsweringBody" : [{"_value" : "Ministry of Defence"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/156459/answer", "answerText" : {"_value" : " As with all prescriptions the Ministry of Defence follows the drug manufacturer's advice which stipulates that Mefloquine (commercially known as Lariam) should not be taken if you are carrying out complex tasks such as driving, piloting an aircraft or diving. Accordingly, the Department's current policy is that aircrew are not to take Mefloquine.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3428", "label" : {"_value" : "Biography information for Lord Astor of Hever"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Astor of Hever"}
, "dateOfAnswer" : {"_value" : "2014-12-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-01T16:16:54.15Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "11"}
, "answeringDeptShortName" : {"_value" : "Defence"}
, "answeringDeptSortName" : {"_value" : "Defence"}
, "date" : {"_value" : "2014-11-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Armed Forces: Mefloquine"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government whether Lariam (mefloquine) is administered to pilots and air crew serving in the armed forces.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/215", "label" : {"_value" : "Biography information for Baroness Corston"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Corston"}
], "uin" : "HL2901"}
, {"_about" : "http://data.parliament.uk/resources/156460", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/156460/answer", "answerText" : {"_value" : " The current edition of the British National Formulary lists the price of Lariam (mefloquine) as £14.53 for a pack of 8 tablets and the price of Malarone (proguanil hydrochloride with atovaquone) as £25.21 for a pack of 12 tablets.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-12-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-02T12:37:24.513Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Malaria"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what the unit cost is of (1) Lariam (mefloquine), and (2) malarone.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/215", "label" : {"_value" : "Biography information for Baroness Corston"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Corston"}
], "uin" : "HL2902"}
, {"_about" : "http://data.parliament.uk/resources/156461", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/156461/answer", "answerText" : {"_value" : " Full meetings of the Advisory Committee for Malaria Prevention occurred in March and August of 2012 and January and December of 2013. The next full meeting is planned for January 2015. There was a sub-group meeting in 2014 to approve the 2014 version of the Guidelines for malaria prevention in travellers from the UK<\/em>.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-12-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-02T12:41:24.367Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Malaria"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government on how many occasions the Advisory Committee for Malaria Prevention has met in the last two years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/215", "label" : {"_value" : "Biography information for Baroness Corston"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Corston"}
], "uin" : "HL2903"}
, {"_about" : "http://data.parliament.uk/resources/156462", "AnsweringBody" : [{"_value" : "Foreign and Commonwealth Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/156462/answer", "answerText" : {"_value" : " We are deeply concerned by the Cooper Review and believe it is essential that the UN communicate its findings openly and transparently. We will urge the UN to undertake a thorough assessment of the issues raised and publish the full report of the Cooper Review.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3474", "label" : {"_value" : "Biography information for Baroness Anelay of St Johns"}
}
, "answeringMemberPrinted" : {"_value" : "Baroness Anelay of St Johns"}
, "dateOfAnswer" : {"_value" : "2014-12-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-01T15:18:16.227Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "16"}
, "answeringDeptShortName" : {"_value" : "Foreign and Commonwealth Office"}
, "answeringDeptSortName" : {"_value" : "Foreign and Commonwealth Office"}
, "date" : {"_value" : "2014-11-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Sudan"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government whether they will instruct the United Kingdom's representative at the United Nations Security Council to call on the Secretary General to publish the full report of the Cooper Review team on the United Nations Mission in Darfur, rather than the summary given to members of the Security Council.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/738", "label" : {"_value" : "Biography information for Lord Alton of Liverpool"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Alton of Liverpool"}
], "uin" : "HL2904"}
, {"_about" : "http://data.parliament.uk/resources/156463", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/156463/answer", "answerText" : {"_value" : " The Human Fertilisation and Embryology Authority has advised that it has not undertaken such an analysis but that it plans to do so.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-12-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-02T12:41:51.237Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "IVF"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government, further to the Written Answer by Earl Howe on 17 November (HL2643), whether the records held by the Human Fertilisation and Embryology Authority on foetal reductions carried out in the first trimester and early in the second trimester following in vitro fertilisation or donor insemination indicate that it has any significant impact on \"the single biggest risk to the health and welfare of children born following fertility treatment\"; if so, what is the effect and how it is represented numerically; and to what extent the recommendation that prevention of multiple pregnancies through single embryo transfer should be preferred to multi-foetal pregnancy reduction reflects a lack of efficacy of foetal reductions in reducing risks or emotional trauma associated with such a procedure.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/738", "label" : {"_value" : "Biography information for Lord Alton of Liverpool"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Alton of Liverpool"}
], "uin" : "HL2905"}
, {"_about" : "http://data.parliament.uk/resources/156464", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/156464/answer", "answerText" : {"_value" : " As stated in my Written Answer of 17 November 2014 (Official Report<\/em>, col. WA59) the mitochondrial diseases listed in Annex D of the mitochondrial donation consultation document are diseases caused by an inherited mutation in mitochondrial DNA. As such, none of these diseases are caused by a nuclear gene defect. Mitochondrial disorders caused by a nuclear gene defect are distinct from those listed in Annex D.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-12-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-02T12:42:21.587Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "IVF"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government, further to the Written Answer by Earl Howe on 17 November (HL2642), whether they consider that any of the mitochondrial diseases listed in Annex D of the \"Mitochondrial Donation\" consultation document could ever arise from a nuclear gene defect; and if so, what is their assessment of the frequency with which it occurs and how that has been reflected when discussing mitochondrial diseases that may be candidates for pronuclear transfer or spindle-chromosomal complex transfer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/738", "label" : {"_value" : "Biography information for Lord Alton of Liverpool"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Alton of Liverpool"}
], "uin" : "HL2906"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-dateTabled=2019-06-10&min-ddpCreated=2014-10-29T22%3A13%3A42.177Z&max-ddpModified=2015-02-06T19%3A41%3A51.093Z&dateTabled=2014-11-18", "page" : 0, "startIndex" : 1, "totalResults" : 46, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}